内镜检查前COVID-19聚合酶链反应检测的经济学分析
该研究通过回顾性分析COVID-19疫情期间内镜使用量作为基线,建立计算机模型比较三种策略:仅紧急指征内镜、半紧急指征检测、全部患者检测。结论认为PCR检测是美国重启内镜实践的有效策略,应在疫情第二阶段实施。
要点
- 疫情期间内镜量仅为预期的12.7%,策略2和3可安全恢复半紧急和择期内镜。
- 每例检测投入22美元和105美元分别完成基线19.4%和95.3%的内镜检查。
核心结论
- PCR检测是美国重启内镜实践的有效策略。
- PCR筛查应在疫情第二阶段实施,即医疗系统能够检测并隔离所有疑似COVID-19病例时。
研究设计与样本
- 回顾性分析COVID-19疫情期间内镜使用量作为基线参考。
- 计算机模型比较三种策略:策略1仅紧急指征内镜;策略2半紧急指征检测;策略3全部患者检测。
- 分析基于当前COVID-19患病率及预测的5%和10%患病率。
- 主要结局为执行和/或取消的操作数量;次要结局为直接成本、报销、使用的个人防护装备和感染人员。
- 疾病患病率、检测准确性和成本来自文献。
主要发现
- COVID-19疫情期间内镜量为预期的12.7%。
- 策略2和3是恢复半紧急和择期内镜的安全有效干预措施。
- 每例检测投入22美元和105美元分别完成基线内镜的19.4%和95.3%。
- 检测4700例患者后出现假阴性结果(或本研究中心应用策略2三个月时)。
关键数值与推荐
- 策略2每例检测投入22美元,完成基线内镜的19.4%。
- 策略3每例检测投入105美元,完成基线内镜的95.3%。
- 检测4700例患者后出现假阴性结果(或本研究中心应用策略2三个月时)。
- 全美实施PCR检测1周分别有65和325名医护人员感染。
临床怎么用
- 作者认为PCR检测是美国重启内镜实践的有效策略。
- 作者建议PCR筛查应在疫情第二阶段实施,即医疗系统能够检测并隔离所有疑似COVID-19病例时。
- 本研究中心应用策略2三个月时出现假阴性结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The novel coronavirus disease 2019 (COVID-19) pandemic has limited endoscopy utilization, causing significant health and economic losses. We aim to model the impact of polymerase chain reaction (PCR) testing into resuming endoscopy practice. METHODS: We performed a retrospective review of endoscopy utilization during the COVID-19 pandemic for a baseline reference. A computer model compared 3 approaches: strategy 1, endoscopy for urgent indications only; strategy 2, testing for semiurgent indications; and strategy 3, testing all patients. Analysis was made under current COVID-19 prevalence and projected prevalence of 5% and 10%. Primary outcomes were number of procedures performed and/or canceled. Secondary outcomes were direct costs, reimbursement, personal protective equipment used, and personnel infected. Disease prevalence, testing accuracy, and costs were obtained from the literature. RESULTS: During the COVID-19 pandemic, endoscopy volume was 12.7% of expected. Strategies 2 and 3 were safe and effective interventions to resume endoscopy in semiurgent and elective cases. Investing 22 U.S. dollars (USD) and 105 USD in testing per patient allowed the completion of 19.4% and 95.3% of baseline endoscopies, respectively. False-negative results were seen after testing 4700 patients (or 3 months of applying strategy 2 in our practice). Implementing PCR testing over 1 week in the United States would require 13 and 64 million USD, with a return of 165 and 767 million USD to providers, leaving 65 and 325 healthcare workers infected. CONCLUSIONS: PCR testing is an effective strategy to restart endoscopic practice in the United States. PCR screening should be implemented during the second phase of the pandemic, once the healthcare system is able to test and isolate all suspected COVID-19 cases.
引用
- Corral JE, Hoogenboom SA, Kröner PT, et al. COVID-19 polymerase chain reaction testing before endoscopy: an economic analysis. Gastrointest Endosc. 2020. PMID: 32360302. doi:10.1016/j.gie.2020.04.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。